Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 8/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.33 |
| ▸ | HTR3B | O95264 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.33 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3306839 | 0.86 | TTR (0.47) | ADRB2ADRB1HSD11B1KDRPDK1 | |
| SCHEMBL5166345 | 0.84 | NPFFR2 (0.44) | ADRB2ADRB1HSD11B1KDRNPFFR2 | |
| SCHEMBL28644289 | 0.84 | ADRB2 (0.40) | ADRB2ADRB1HSD11B1KDRNPFFR2 | |
| Hydrochloric Acid SCHEMBL7280694 | 0.84 | TTR (0.46) | ADRB2ADRB1HSD11B1KDRPDK1 | |
| SCHEMBL31749059 | 0.84 | NPFFR2 (0.44) | ADRB2ADRB1HSD11B1KDRNPFFR2 | |
| SCHEMBL11632983 | 0.82 | GSK3B (0.42) | ADRB2RAB9A | |
| SCHEMBL9446664 | 0.81 | ADRB2 (0.39) | ADRB2ADRB1HSD11B1KDRNPFFR2 | |
| SCHEMBL12433188 | 0.81 | ADRB2 (0.45) | ADRB2ADRB1HSD11B1KDRNPFFR2 | |
| SCHEMBL3002757 | 0.80 | HSD11B1 (0.50) | HSD11B1 | |
| SCHEMBL5167276 | 0.80 | GSK3B (0.44) | ADRB2ADRB1HSD11B1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1439164-B1 | NOVEL PHENYLETHANOLAMINE COMPOUNDS HAVING BETA2-ACCEPTOR EXCITATORY FUNCTION AND THEIR PREPARATION METHOD | UNIV SHENYANG PHARMACEUTICAL (CN) | 2007-04-11 | — | — | EP | disclosed |
| US-7098364-B2 | Phenylethanolamine compounds as β2-receptor agonists, and methods of use and preparation thereof | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2006-08-29 | — | — | US | disclosed |
| US-20040266867-A1 | Novel phenylethanolamine compounds having &bgr;<sb>2</sb>acceptor excitatory function and their preparation method | JINZHOU JIUTAI PHARMACEUTICAL CO., LTD. CHINA (CN) | 2004-12-30 | — | — | US | disclosed |
| EP-1439164-A1 | NOVEL PHENYLETHANOLAMINE COMPOUNDS HAVING BETA2-ACCEPTOR EXCITATORY FUNCTION AND THEIR PREPARATION METHOD | Shenyang Pharmaceutical University (CN) | 2004-07-21 | — | — | EP | disclosed |
| EP-0158532-B1 | Use of 4-amino-N-(1-azabicyclo[2.2.2]oct-3-yl)-5-chloro-2-methoxybenzamide for the manufacture of a medicament having anti-emetic activity. | SYNTHELABO (FR) | 1994-06-22 | — | — | EP | disclosed |
| US-5273972-A | [(2-diakylaminomethyl)-3-quinuclidinyl]-benzamides and benzoates | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-12-28 | — | — | US | disclosed |
| US-5236931-A | Treating anxiety, psychosis, cognitive dysfunction, migrane, cluster headache, trigeminal neuralgia emesis and impaired gastric motility | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-08-17 | — | — | US | disclosed |
| US-5206246-A | Anxiolytic agents | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-04-27 | — | — | US | disclosed |
| EP-0306345-B1 | 2-ALKOXY-N-(1-AZABICYCLO(2.2.2)-OCT-3-YL) BENZAMIDES AND THIOBENZAMIDES HAVING AN ANTISCHIZOPHRENIC ACTIVITY | SYNTHELABO (FR) | 1993-04-14 | — | — | EP | disclosed |
| EP-0353372-B1 | Antischizophrenic-S-N-(1-azabicyclo[2.2.2.]oct-3-yl) benzamides and thiobenzamides | SYNTHELABO (FR) | 1993-02-03 | — | — | EP | disclosed |
| EP-0353372-A1 | Antischizophrenic-S-N-(1-azabicyclo[2.2.2.]oct-3-yl) benzamides and thiobenzamides | SYNTHELABO (FR) | 1990-02-07 | — | — | EP | disclosed |
| US-4877794-A | 2-Alkoxy-n-(1-azabicyclo(2.2.2)oct-3-yl) benzamide and thiobenzamide compositions and the use thereof to treat schizophrenia | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-10-31 | — | — | US | disclosed |
| EP-0311724-A1 | Anxiolytic-R-N-(1-azabicyclo[2.2.2]oct-3-yl) benzamides and thiobenzamides | SYNTHELABO (FR) | 1989-04-19 | — | — | EP | disclosed |
| EP-0306345-A2 | 2-Alkoxy-n-(1-azabicyclo(2.2.2)-oct-3-yl) benzamides and thiobenzamides having an antischizophrenic activity | SYNTHELABO (FR) | 1989-03-08 | — | — | EP | disclosed |
| EP-0272052-A1 | Anxiolytic-N-(1-Azabicyclo[2.2.2]Oct-3-yl) Benzamides and Thobenzamides | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1988-06-22 | — | — | EP | disclosed |
| US-4717563-A | 2-alkoxy-N-(1-azabicyclo(2.2.2)oct-3-yl) benzamides and thiobenzamides in a method for alleviating emesis caused by non-platinum anticancer drugs | A. H. ROBINS COMPANY, INC. (US) | 1988-01-05 | — | — | US | disclosed |
| EP-0240180-A1 | 2-alkoxy-N-(1-azabicyclo[2.2.2]-oct-3-yl) benzamides and thiobenzamides in the alleviation of emesis caused by non-platinum anticancer drugs | SYNTHELABO (FR) | 1987-10-07 | — | — | EP | disclosed |
| US-4593034-A | 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides | A. H. ROBINS COMPANY, INC. (US) | 1986-06-03 | — | — | US | disclosed |
| EP-0158532-A2 | Use of 4-amino-N-(1-azabicyclo[2.2.2]oct-3-yl)-5-chloro-2-methoxybenzamide for the manufacture of a medicament having anti-emetic activity. | SYNTHELABO (FR) | 1985-10-16 | — | — | EP | disclosed |
| US-4093734-A | ANTIULCER AGENTS, ANTIEMETICS, ANTICONVULSANTS | BOEHRINGER INGELHEIM GMBH (DT) | 1978-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266867-A1 | Novel phenylethanolamine compounds having &bgr;<sb>2</sb>acceptor excitatory function and their preparation method | ADRB2, ADRB3, CHRM3 | ADRB2 1/4885ADRB1 4/4885HSD11B1 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.